Bisphosphonate therapy of reflex sympathetic dystrophy syndrome

Annals of the Rheumatic Diseases

Volumn 56, Issue 3, 1997, Pages 201-204

  Adami, S ^a,b   Fossaluzza, V ^c   Gatti, D ^a   Fracassi, E ^a   Braga, V ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Ospedale di Valeggio   (Italy)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANALGESIC AGENT; CALCITONIN; PLACEBO;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPATHETIC DYSTROPHY;

EID: 0030989779     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.56.3.201     Document Type: Article

References (17)

1. Kozin F, McCarty DJ, Sims J, Genant H. The reflex sympathetic dystrophy syndrome. I. Clinical and histological studies: Evidence for bilaterality, response to corticosteroids and articular involvement. Am J Med 1976;60: 321-31.
2. Kozin F, Ryan LM, Carrera GF, Soin JS, Wortmann RL. The reflex sympathetic distrophy syndrome. III Scintigraphic studies. Further evidence for the therapeutic efficacy of systemic steroids and proposed diagnostic criteria. Am J Med 1981;70:23-30.
3. Doury P, Dirheimer Y, Pattin S. Algodystrophy: Diagnosis and therapy of a frequent disease of the locomotor aparatus.New York: Springer Verlag, 1981.
4. Doury P. Algodystrophy. Reflex sympathetic dystrophy syndrome. Clin Rheumatol 1988;7:173-80.
5. Lenggenhager K. Sudeck's osteodystrphy: its pathogenesis, prophylaxis and therapy. Minn Med 1971;54:967-77.
6. Fleisch H. Bisphosphonates in bone disease. From the laboratory to the patient. Berne:H Fleisch, 1993.
7. Rehman MT, Clayson AD, Marsh D, Adams J, Cantrill JA, Anderson DC. Treatment of reflex sympathetic dystrophy with intravenous pamidronate. Bone 1992;13:116-8.
8. Selby PL, Young MJ, Boulton AJM. Bisphosphonates: a new treatment for diabetic Charcot neuroarthropathy? Diabetic Medicine 1994;11:28-31.
9. Adami S, Salvagno G, Guerrera G, Montesanti F, Garavelli S, Rosini S, et al. Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybuthylidene-1,1-bisphsphonate. Calcif Tissue Int 1986;39:226-9.
10. Adami S, Bolzicco GB, Rizzo A, Salvagno G, Bertoldo F, Rossini M, et al. The use of dichloromethylene bisphosphonate and aminobutane-bisphosphonate in hypercalcemia of malignancy. Bone Mineral 1987;2:395-404.
11. Tepperman PS, Grayson ND, Helbert L, Jimenez J, Williams JI. Reflex sympathetic dystrophy in hemiplegia. Arch Phys Med Rehabil 1984;65:442-7.
12. Adami S, Zamberlan N, Gatti D, Braga V, Broggini M, Rossini M, et al. Computed radiographic absortiometry and morphometry in the assessment of postmenopausal bone loss. Osteoporosis Int 1996;6:8-13.
13. Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987;41: 326-31.
14. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-9.
15. Adami S, Passeri M, Ortolani S, Broggini M, Carratelli L, Caruso I, et al. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995;17:383-90.
16. Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
17. Saury A, Pecherstorfer M, Zimmer-Roth I, Fioroni L, Markert M, Ludwig H, et al. Interleukin-6 and tumor necrosis factor ∝ levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 1996;18:133-9.